167 related articles for article (PubMed ID: 28470575)
1. Association between Level of Tumor Markers and Development of VTE in Patients with Pancreatic, Colorectal and Ovarian Ca: Retrospective Case- Control Study in Two Community Hospitals.
Awkar N; Amireh S; Rai S; Shaaban H; Guron G; Maroules M
Pathol Oncol Res; 2018 Apr; 24(2):283-287. PubMed ID: 28470575
[TBL] [Abstract][Full Text] [Related]
2. [Cancer clearance for "unprovoked" venous thromboembolism cases].
Ye W; Chen Y; Li M; Jiang C; Li D; Liu C
Zhonghua Yi Xue Za Zhi; 2014 Apr; 94(15):1143-6. PubMed ID: 24924711
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and associations of VTE in patients with newly diagnosed lung cancer.
Zhang Y; Yang Y; Chen W; Guo L; Liang L; Zhai Z; Wang C;
Chest; 2014 Sep; 146(3):650-658. PubMed ID: 24676401
[TBL] [Abstract][Full Text] [Related]
4. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
5. High incidence of silent venous thromboembolism before treatment in ovarian cancer.
Satoh T; Oki A; Uno K; Sakurai M; Ochi H; Okada S; Minami R; Matsumoto K; Tanaka YO; Tsunoda H; Homma S; Yoshikawa H
Br J Cancer; 2007 Oct; 97(8):1053-7. PubMed ID: 17895896
[TBL] [Abstract][Full Text] [Related]
6. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.
Claussen C; Rausch AV; Lezius S; Amirkhosravi A; Davila M; Francis JL; Hisada YM; Mackman N; Bokemeyer C; Schmalfeldt B; Mahner S; Langer F
Thromb Res; 2016 May; 141():39-48. PubMed ID: 26967531
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic value of carcinoembryonic antigen and carcinoma antigen 19-9 for colorectal carcinoma.
Zhang SY; Lin M; Zhang HB
Int J Clin Exp Pathol; 2015; 8(8):9404-9. PubMed ID: 26464695
[TBL] [Abstract][Full Text] [Related]
8. Postoperative carcinoembryonic antigen as a complementary tumor marker of carbohydrate antigen 19-9 in pancreatic ductal adenocarcinoma.
Kim J; Lee YS; Hwang IK; Kang BK; Cho JY; Yoon YS; Han HS; Hwang JH
J Korean Med Sci; 2015 Mar; 30(3):259-63. PubMed ID: 25729247
[TBL] [Abstract][Full Text] [Related]
9. CA 19-9 as a marker in addition to CEA to monitor colorectal cancer.
Stiksma J; Grootendorst DC; van der Linden PW
Clin Colorectal Cancer; 2014 Dec; 13(4):239-44. PubMed ID: 25442815
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 doubling time in pancreatic cancer as a predictor of venous thromboembolism: a hospital database study.
Peippo MH; Kurki S; Seppänen H; Lassila R; Carpén O
Acta Oncol; 2020 Feb; 59(2):237-241. PubMed ID: 31650877
[No Abstract] [Full Text] [Related]
11. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
[TBL] [Abstract][Full Text] [Related]
13. CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.
Tsavaris N; Kosmas C; Papadoniou N; Kopterides P; Tsigritis K; Dokou A; Sarantonis J; Skopelitis H; Tzivras M; Gennatas K; Polyzos A; Papastratis G; Karatzas G; Papalambros A
J Chemother; 2009 Dec; 21(6):673-80. PubMed ID: 20071292
[TBL] [Abstract][Full Text] [Related]
14. Incidence of venous thromboembolism in patients with solid cancers in Japan: retrospective study of 2735 patients.
Nose T; Imamura Y; Ohata S; Kimbara S; Miyata Y; Hyogo Y; Fujishima Y; Funakoshi Y; Toyoda M; Kiyota N; Minami H
Int J Hematol; 2021 Sep; 114(3):319-324. PubMed ID: 34091877
[TBL] [Abstract][Full Text] [Related]
15. Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Okulczyk B
Dig Dis Sci; 2005 Jun; 50(6):1019-24. PubMed ID: 15986847
[TBL] [Abstract][Full Text] [Related]
16. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
[TBL] [Abstract][Full Text] [Related]
17. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of risk factors for venous thromboembolism in Chinese women with epithelial ovarian cancer.
Wu X; Xue X; Tang J; Cheng X; Tian W; Jiang R; Zang R
Int J Gynecol Cancer; 2013 Jan; 23(1):65-72. PubMed ID: 23196757
[TBL] [Abstract][Full Text] [Related]
19. Incidence and risk factors of preoperative venous thromboembolism and pulmonary embolism in patients with ovarian cancer.
Liang S; Tang W; Ye S; Xiang L; Wu X; Yang H
Thromb Res; 2020 Jun; 190():129-134. PubMed ID: 32361343
[TBL] [Abstract][Full Text] [Related]
20. Tissue Factor Pathway Inhibitor 2: A Novel Biomarker for Predicting Asymptomatic Venous Thromboembolism in Patients with Epithelial Ovarian Cancer.
Yamanaka S; Miyake R; Yamada Y; Kawaguchi R; Ootake N; Myoba S; Kobayashi H
Gynecol Obstet Invest; 2022; 87(2):133-140. PubMed ID: 35613543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
